Here's a strange one for you: Iterum Therapeutics plc (ITRM) shares are up 140% on Monday. The reason? The company announced it's filing a winding-up petition in Ireland that could lead to its complete dissolution. Yes, you read that correctly. The stock is soaring because the company might cease to exist.

At last check, shares had jumped to $0.0883 with trading volume hitting a staggering 681.37 million shares. That's about 269 times the 100-day average of 2.53 million shares. This is what happens in the world of distressed, low-priced biotech stocks—sometimes the worse the news, the more speculative trading activity you get, even when the risks include delisting or total equity loss.

The petition will be heard in Ireland's High Court on April 13, 2026. If the court grants a winding-up order, Joint Provisional Liquidators would be appointed, eventually leading to the company's dissolution. The decision comes down to simple math: limited cash resources and an inability to meet Nasdaq listing requirements have left Iterum with "no viable strategic alternatives." That's corporate-speak for "we're out of options."

As part of this winding-down process, the company is likely to withdraw its product ORLYNVAH from the U.S. market. That's the oral antibiotic aimed at treating urinary tract infections. The withdrawal will follow FDA procedures and involve consultations with third-party service providers.

Now here's where it gets interesting. Just last month, in February, Iterum provided a business update that included several positive developments. The company signed a rebate agreement with a third top-tier Medicare Part D pharmacy benefit manager, complementing existing deals with the other two. This expands potential formulary access for ORLYNVAH to over 3.5 million Medicare lives, with coverage expected as early as this quarter.

Iterum also secured U.S. patent No. 12,544,337 covering its bilayer tablet combining sulopenem etzadroxil and probenecid, including manufacturing methods and use in treating conditions like uncomplicated urinary tract infections. The patent is expected to expire in December 2039 and is eligible for Orange Book listing, which would bring the total to five listed U.S. patents.

Meanwhile, the FDA has indicated that supporting ORLYNVAH as a step-down therapy for complicated urinary tract infections will require substantial evidence from a well-designed clinical trial via a supplemental NDA. The agency advised Iterum to pursue a Type C meeting to align on trial design and endpoints.

So let's recap: The company is expanding Medicare access for its drug while planning to withdraw it from the market. It's securing patents that extend to 2039 while preparing for potential dissolution in 2026. And the stock is up 140% on news that could mean the end of the company. Welcome to biotech investing, where sometimes the story doesn't have to make sense for the stock to move.